Clinical risk factors for invasive aspergillosis
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Despite improvements in the antifungal armamentarium and diagnostic modalities, invasive aspergillosis (IA) remains an important cause of morbidity and mortality in immunocompromised patients. There is an emergence of non-traditional groups at risk for IA, including intensive care unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and patients on immunomodulating drugs (TNF-α inhibitors). Identification of clinical risk factors for IA may help in determining which patients require risk modification and other prevention measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Wald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742
Research works printed but not linked: 5
- Guinea J, 2009, Clin Microbiol Infect
- 10.4065/83.2.181 · DOI
- Bobba RK, 2004, Clin Microbiol Infect, 10, 679, 10.1111/j.1469-0691.2004.00912.x · doi:10.1111/j.1469-0691.2004.00912.x
- Manz M, 2009, Gut, 59, 149, 10.1136/gut.2008.161638 · doi:10.1136/gut.2008.161638
- Salavert M, 2009, Rev Iberoam Micol, 26, 213, 10.1016/j.riam.2009.01.001 · doi:10.1016/j.riam.2009.01.001
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Neofytos, D., Chatzis, O., Nasioudis, D., Boely Janke, E., Doco Lecompte, T., Garzoni, C., Berger, C., Cussini, A., Boggian, K., Khanna, N., et al. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12898 · Cited by 108
Mortensen, K. L., Johansen, H. K., Fuursted, K., Knudsen, J. D., Gahrn-Hansen, B., Jensen, R. H., Howard, S. J., & Arendrup, M. C. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1229-7 · Cited by 92
“In addition, patients in intensive care units (ICU), recipients of solid organ transplants and those suffering from chronic obstructive pulmonary disease (COPD) are also at risk of IA [3–5].”
BackgroundRecent Advances in Diagnosing Chronic Pulmonary Aspergillosis
Takazono, T., & Izumikawa, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01810 · Cited by 71
“Patients with defects in cell-mediated immunity, including those with neutropenia due to cytotoxic chemotherapy, or T-cell dysfunction due to corticosteroid or other immunosuppressive therapy are at risk of developing invasive pulmonary aspergillosis (IPA) characterized by hyphal invasion of lung tissues and dissemina…”
Background
Metadata
- Authors
- Baddley, J. W.
- Venue
- Medical Mycology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04
- Volume
- 49
- Issue
- S1
- Pages
- S7-S12
- ISSN
- 0268-1218 (ISSN-L)
- 1369-3786
- 1460-2709
- OpenAlex
- W2026574962
- Cited by
- 203
- References
- 56
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical risk factors for invasive aspergillosis. https://app.cochat.ai/papers/10.3109/13693786.2010.505204
- The paper
- Baddley, J. W. (2011). Clinical risk factors for invasive aspergillosis. Medical Mycology. https://doi.org/10.3109/13693786.2010.505204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.